Unknown PHASE2 INTERVENTIONAL 2-arm NCT05225844

An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal

Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal Cancer With Previous Standard Treatment Failure ：an Exploratory, Single-arm, Open-label, Phase II Trial

Sponsor: Harbin Medical University

Conditions Gastrointestinal Cancer Immunotherapy Targeted Therapy

Interventions Apatinib Mesylate Camrelizumab

Updated 4 times since 2022 Last updated: Feb 4, 2022 Started: Jan 1, 2019 Primary completion: Feb 1, 2022 Completion: Oct 1, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Gastrointestinal Cancer and Immunotherapy and is currently ongoing. Harbin Medical University leads this study, which shows 4 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Mar 2024 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Mar 2022 — Mar 2024 [monthly]

Recruiting PHASE2

First recorded

Jan 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Harbin Medical University

Data source: Harbin Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Harbin, China